Several studies have examined the predictive value of KRAS mutation in codon 61 and/or 146 in metastatic colorectal cancer treated with anti-EGFR therapy (cetuximab or panitumumab)[26-28,41,43]. Here, KRAS is linked to metastatic colorectal cancer.